In the News

48753 ksm logo_biz3_1.png

Our new study published today in JAMA "Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine"

Jama Network

Dec 1, 2021

48753 ksm logo_biz3_1.png

We’re super excited with our Deputy Head of KSM Dr Sivan Gazit for making it into the TheMarker “40 under 40” most promising list.

TheMarker(In Hebrew)

Nov 8, 2021

48753 ksm logo_biz3_1.png

Nature Communications published today our study "Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine".

Nature Communications

Nov 4, 2021

48753 ksm logo_biz3_1.png

Nature Medicine magazine published today our joint study with Technion institute: "Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2".

Nature Medicine

Nov 2, 2021

48753 ksm logo_biz3_1.png

Published today on Haaretz newspaper:  Our joint preprint with Technion institute: "Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine"

Haaretz (In Hebrew)

Sep 19, 2021

48753 ksm logo_biz3_1.png

Published on Ynet- Our preprint “Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine”

ynet (In Hebrew)

Sep 3, 2021

48753 ksm logo_biz3_1.png

Published today on Doctorsonly.
Our preprint: "Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections"

Doctorsonly (in Hebrew)

Sep 2, 2021

48753 ksm logo_biz3_1.png

Published today in Science magazine: our preprint "Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine"

Science

September 1, 2021

48753 ksm logo_biz3_1.png

Published today in Science magazine: our preprint "Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections"

Science

Aug 27, 2021

48753 ksm logo_biz3_1.png

New collaboration with Ibex - introducing the world first AI powered solution for gastrointestinal cancer diagnosis at Maccabi Healthcare Services.

AIthority

Aug 25, 2021

48753 ksm logo_biz3_1.png

Nature News new story - our study assessing the correlation between time-from-vaccine and incidence of breakthrough infection in Nature News. We found that Individuals who were vaccinated in January 2021 had a 2.26-fold increased risk for breakthrough infection compared to individuals who were vaccinated in April 2021

Nature.com

Aug 5, 2021

48753 ksm logo_biz3_1.png

Our joint research with Tel Aviv University published in JAMA closed an important knowledge gap on the safety and effectiveness of the COVID-19 vaccine, by examining the pregnant population which was excluded from the clinical trials.

Ynet

July 25, 2021

48753 ksm logo_biz3_1.png

Just published in Reuters Health - Our new study on COVID-19 vaccine effectiveness in patients with Inflammatory Bowel Disease (IBD)

Reuters Health

July 18, 2021

48753 ksm logo_biz3_1.png

Our study on COVID-19 vaccine effectiveness in patients with Inflammatory Bowel Disease (IBD), published July 2, 2021 in Gastroenterology—the flagship journal of the American Gastroenterology Association.

Gastroenterolgy

July 2, 2021

48753 ksm logo_biz3_1.png

Published today in Doctorsonly

Linkedin

June 13, 2021

48753 ksm logo_biz3_1.png

KSM study in the New York Times!
Our academia-healthcare collaboration with Technion Institute of Technology appearing in the New York Times.
The study "Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals" just published.

New York Times

June 11, 2021

48753 ksm logo_biz3_1.png

Our joint research with Prof. Roy Kishony and his team from Technion Institute "Community-level evidence for Coronavirus vaccine protection of unvaccinated individuals" published today on Nature Medicine Magazine.

Nature Medicine Magazine

June 10, 2021

48753 ksm logo_biz3_1.png

A new research by KSM shows most respondents are in favor of vaccinating 12-16 year olds— men more in favor than women. Furthermore, new insights on additional vaccine doses, mask usage stats and more are described.

Doctors Only ( In Hebrew).

June 6, 2021

48753 ksm logo_biz3_1.png

New KSM research in association with IBM:
Trends in clinical characteristics of severe non-respiratory events related to Coronavirus patients

Linkedin

Apr 18, 2021

48753 ksm logo_biz3_1.png

Our new survey on behaviour attitudes towards preventive measures following Coronavirus vaccination

Linkedin

Apr 14, 2021